# Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant

> **NCT01398501** · PHASE1 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 22 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01398501
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08
- **Primary completion:** 2015-09
- **Final completion:** 2016-08
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2017-03-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01398501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01398501, "Sorafenib Maintenance Therapy for Patients With AML After Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01398501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*